Xynomic Pharmaceuticals, Inc.
2 clinical trials · 2 recruiting · INDUSTRY
Trials by Xynomic Pharmaceuticals, Inc.
RECRUITINGPhase 2NCT03936153
Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell...
An open-label, single-arm, multi-center phase 2 study to evaluate the efficacy and safety of abexinostat, as monotherapy in patients with relapsed or refractory diffuse large...
Sponsor: Xynomic Pharmaceuticals, Inc.Enrolling: 17020 locations
Diffuse Large B-cell Lymphoma (DLBCL)
RECRUITINGPhase 3NCT03592472
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma...
This is a randomized, Phase 3, double-blind, placebo-controlled study of pazopanib plus abexinostat versus pazopanib plus placebo in patients with locally advanced unresectable or...
Sponsor: Xynomic Pharmaceuticals, Inc.Enrolling: 41320 locations
Renal Cell Carcinoma